Figure 2

Compounds triggering transcriptional signatures opposed to the COVID^CS. (A) COVID^CS similarity scores for drug types (CMap Classes) already under study for the treatment of the COVID-19 CS. (B) Drug GSEA analysis of compound classes with a transcriptional signature that negatively correlates to the COVID^CS. Enriched pathways with padj value < 0.05 are shown, as well as their gene ranks, Normalized Enrichment Scores (NES), p-value (pval) and adjusted p-value (padj). (C, D) Enrichment plots of Glucocorticoid receptor agonists (C) and MEK inhibitors (D) resulting from the Drug GSEA analysis mentioned in (B) illustrating the overall negative correlation between the transcriptional signatures triggered by these compounds and the COVID^CS. (E) Similarity scores of the top CMap Classes with an associated transcriptional signature that negatively correlates to the COVID^CS. (F) Similarity scores of specific compounds with a COVID^CS similarity score lower than − 95. MEK inhibitors (blue), RAF/EGFR/MAPK inhibitors (orange) and glucocorticoid receptor agonists (red) are highlighted by the indicated colors.